Galapagos NV
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of …
Biotechnology
BE, Mechelen [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Galapagos NV's gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | - | -2.329 | - | 60 | - | -153 | - | -4 | - | -8 | - | 21 |
| 2016 | - | -0.498 | - | 141 | - | -32 | - | -11 | - | -20 | - | 51 |
| 2017 | - | -2.084 | - | 175 | - | -137 | - | -14 | - | -24 | - | 63 |
| 2018 | - | -1.247 | - | 307 | - | -82 | - | -25 | - | -43 | - | 111 |
| 2019 | -0.5600 | 5.181 | 288 | 994 | -29 | 341 | -35 | -81 | -367 | -141 | 29 | 362 |
| 2020 | 2.6000 | -4.581 | 844 | 597 | 149 | -301 | 390 | -48 | -57 | -84 | 88 | 217 |
| 2021 | -4.6900 | -2.717 | 478 | 547 | -305 | -178 | -165 | -44 | -702 | -77 | 162 | 199 |
| 2022 | -1.5800 | -1.250 | 484 | 594 | -103 | -82 | -138 | -48 | -165 | -84 | 167 | 216 |
| 2023 | - | -1.142 | - | 561 | - | -75 | - | -45 | - | -79 | - | 204 |
| 2024 | - | -0.015 | - | 337 | - | 0.96 | - | -27 | - | -47 | - | 122 |
| 2025 | - | -1.082 | - | 320 | - | -71 | - | -26 | - | -45 | - | 116 |
| 2026 | - | -1.175 | - | 358 | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | -2.103 | - | 298 | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | -1.980 | - | 351 | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the grade
Galapagos NV can't present the grade consensus distribution right now.
Price Target Consensus
Price Then
$n/a
Price Target
$n/a
Price Now
$24.66